Opinion|Videos|November 8, 2024
Unmet Needs in Generalized Myasthenia Gravis
Key Takeaways
- Current MG treatments often have limited efficacy and significant side effects, necessitating more effective and targeted therapies.
- Early and accurate diagnosis is crucial, highlighting the need for better diagnostic tools in MG management.
Panelists discuss how certain aspects of myasthenia gravis management remain challenging, identifying ongoing unmet needs in diagnosis, treatment, and patient care.
Advertisement
Video content above is prompted by the following:
- What continue to be unmet needs in myasthenia gravis?
Advertisement
Related to this article
As diabetes drugs are tested for repurposing in Alzheimer disease, the negative phase 3 EVOKE and EVOKE+ results for oral semaglutide have moved attention toward prevention and earlier, combination-based approaches.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
At a NeurologyLive Clinical Forum in Philadelphia, Chafic Karam, MD, chief of neuromuscular medicine at Penn Medicine, discussed treatment sequencing in myasthenia gravis.
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
3
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
4
Headlining Current Advances and Challenges in Multiple Sclerosis Care
5